Business Description

Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Name Current Vs Industry Vs History
Cash-To-Debt 48.79
Equity-to-Asset 0.93
Debt-to-Equity 0.02
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Beneish M-Score -2.36
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
6-1 Month Momentum % 151.98
12-1 Month Momentum % 177.65

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 21.27
Quick Ratio 21.27
Cash Ratio 20.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -103.1
Shareholder Yield % -64.14

Financials (Next Earnings Date:2024-05-05 Est.)

SRRA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SRRA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Sierra Oncology Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -6.77
Beta 0
Volatility % 73.02
14-Day RSI 0
14-Day ATR ($) 0.16
20-Day SMA ($) 0
12-1 Month Momentum % 177.65
52-Week Range ($) 14.91 - 55.19
Shares Outstanding (Mil) 24.42

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sierra Oncology Inc Filings

Filing Date Document Date Form
No Filing Data

Sierra Oncology Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Sierra Oncology Inc Frequently Asked Questions

What is Sierra Oncology Inc(SRRA)'s stock price today?
The current price of SRRA is $54.99. The 52 week high of SRRA is $55.19 and 52 week low is $14.91.
When is next earnings date of Sierra Oncology Inc(SRRA)?
The next earnings date of Sierra Oncology Inc(SRRA) is 2024-05-05 Est..
Does Sierra Oncology Inc(SRRA) pay dividends? If so, how much?
Sierra Oncology Inc(SRRA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1